COMPUMEDICS PORTABLE SOMTÉ SYSTEM GIVEN GO-AHEAD BY US FDA

Compumedics today announced that the US FDA has granted approval to market the company’s portable Somté sleep-cardiology recording system in the United States.

Australian medical technology company Compumedics Ltd (ASX:CMP) today announced that the US FDA has granted approval to market the company’s portable Somté sleep-cardiology recording system in the United States.

The potential market for Somté in the United States is estimated to be of the order of US$130 million per annum. This announcement follows recent approval to market Somté in Canada and last year’s European Union, Australian and Japanese regulatory approvals.